Response Genetics concludes $7.89 million private placement of stock

Executive insiders participate in offering at $1.50 per common share

By Devika Patel

Knoxville, Tenn., Feb. 6 - Response Genetics, Inc. completed a $7.89 million private placement of stock on Feb. 2, according to an 8-K filed Monday with the Securities and Exchange Commission.

The company sold 5,257,267 common shares at $1.50 per share. The price per share is a 27.19% premium to the Feb. 1 closing share price of $1.18.

Investors included chairman of the board of directors and chief executive officer Thomas A. Bologna, vice president and chief financial officer David O'Toole, vice president, general counsel and secretary Denise McNairn, lead director Kirk K. Calhoun, director Michael Metzger, director Gary D. Nusbaum, director Michael Serruya and director David Wurzer. A fund affiliated with director Richard van den Broek also participated.

Response Genetics is a Los Angeles company that researches and develops clinical diagnostic tests for cancer.

Issuer:	Response Genetics, Inc.
Issue:	Common shares
Amount:	$7,885,900
Shares:	5,257,267
Price:	$1.50
Warrants:	No
Investors:	Thomas A. Bologna, David O'Toole, Denise McNairn, Kirk K. Calhoun, Michael Metzger, Gary D. Nusbaum, Michael Serruya, David Wurzer, Richard van den Broek
Settlement date:	Feb. 2
Stock symbol:	Nasdaq: RGDX
Stock price:	$1.53 at close Feb. 2
Market capitalization:	$34.19 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.